Cataldo Fabian, Chiwaula Levison, Nkhata Misheck, van Lettow Monique, Kasende Florence, Rosenberg Nora E, Tweya Hannock, Sampathkumar Veena, Hosseinipour Mina, Schouten Erik, Kapito-Tembo Atupele, Eliya Michael, Chimbwandira Frank, Phiri Sam
*Medical and Research Department, Dignitas International, Zomba, Malawi; †Chancellor College, University of Malawi, Zomba, Malawi; ‡The University of North Carolina Project, Lilongwe, Malawi; §The Lighthouse Trust, Lilongwe, Malawi; ‖mothers2mothers, Lilongwe, Malawi; ¶Management Sciences for Health, Lilongwe, Malawi; #College of Medicine, University of Malawi, Blantyre, Malawi; and **Ministry of Health, Lilongwe, Malawi.
J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):517-522. doi: 10.1097/QAI.0000000000001273.
Malawi has embarked on a "test-and-treat" approach to prevent mother-to-child transmission (PMTCT) of HIV, known as "Option B+," offering all HIV-infected pregnant and breastfeeding women lifelong antiretroviral therapy (ART) regardless of CD4 count or clinical stage. A cross-sectional qualitative study was conducted to explore early experiences surrounding "Option B+" for patients and health care workers (HCWs) in Malawi.
Study participants were purposively selected across 6 health facilities in 3 regional health zones in Malawi. Semi-structured interviews were conducted with women enrolled in "Option B+" (n = 24), and focus group discussions were conducted with HCWs providing Option B+ services (n = 6 groups of 8 HCWs). Data were analyzed using a qualitative thematic coding framework.
Patients and HCWs identified the lack of male involvement as a barrier to retention in care and expressed concerns at the rapidity of the test-and-treat process, which makes it difficult for patients to "digest" a positive diagnosis before starting ART. Fear regarding the breach of privacy and confidentiality were also identified as contributing to loss to follow-up of women initiated under the Option B+. Disclosure remains a difficult process within families and couples. Lifelong ART was also perceived as an opportunity to plan future pregnancies.
As "Option B+" continues to be rolled out, novel interventions to support and retain women into care must be implemented. These include providing space, time, and support to accept a diagnosis before starting ART, engaging partners and families, and addressing the need for peer support and confidentiality.
马拉维已开始采用“检测与治疗”方法来预防艾滋病毒母婴传播(PMTCT),即所谓的“方案B+”,为所有感染艾滋病毒的孕妇和哺乳期妇女提供终身抗逆转录病毒疗法(ART),无论其CD4细胞计数或临床分期如何。开展了一项横断面定性研究,以探讨马拉维患者和医护人员对“方案B+”的早期体验。
在马拉维3个区域卫生区的6个卫生机构中,有目的地选择了研究参与者。对参加“方案B+”的妇女(n = 24)进行了半结构化访谈,并与提供方案B+服务的医护人员进行了焦点小组讨论(n = 6组,每组8名医护人员)。使用定性主题编码框架对数据进行了分析。
患者和医护人员认为男性参与不足是坚持治疗的一个障碍,并对检测与治疗过程的快速性表示担忧,这使得患者在开始抗逆转录病毒治疗之前难以“消化”阳性诊断结果。对隐私和保密被泄露的担忧也被认为是导致方案B+启动的妇女失访的一个因素。在家庭和夫妻中,披露病情仍然是一个艰难的过程。终身抗逆转录病毒疗法也被视为规划未来怀孕的一个机会。
随着“方案B+”的持续推广,必须实施新的干预措施,以支持妇女并使其坚持接受治疗。这些措施包括在开始抗逆转录病毒治疗之前提供空间、时间和支持以接受诊断,让伴侣和家人参与进来,以及满足同伴支持和保密的需求。